about
The alliance of mesenchymal stem cells, bone, and diabetesAdult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7.Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes.No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial.The effect of the macrobiotic Ma-Pi 2 diet vs. the recommended diet in the management of type 2 diabetes: the randomized controlled MADIAB trial.Breast-feeding and childhood-onset type 1 diabetes: a pooled analysis of individual participant data from 43 observational studies.Increased carotid thickness in subjects with recently-diagnosed diabetes from rural Cameroon.The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type 2 diabetes: a post hoc analysis of the MADIAB trial.Treatment of reactive hypoglycemia with the macrobiotic Ma-pi 2 diet as assessed by continuous glucose monitoring: The MAHYP randomized crossover trial.Assessment of type 1 diabetes risk conferred by HLA-DRB1, INS-VNTR and PTPN22 genes using the Bayesian network approach.Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory studyRecommendations for management of diabetes during Ramadan: update 2015.Adiponectin and bone mass density: The InCHIANTI studyIntroduction into PPPM as a new paradigm of public health service: an integrative view.Effect of calcitriol on bone turnover and osteocalcin in recent-onset type 1 diabetes.A new expression of diabetes: double diabetes.Obesity, autoimmunity, and double diabetes in youth.Evaluation of glycemic variability in well-controlled type 2 diabetes mellitus.Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trialsBone health as a function of adipokines and vitamin D pattern in elderly patients.Double diabetes: a mixture of type 1 and type 2 diabetes in youth.Effect of ghrelin on bone mass density: the InChianti studyIs glucose control important for prevention of cardiovascular disease in diabetes?Review of clinical trials: update on oral insulin spray formulation.Body weight and beauty: the changing face of the ideal female body weight.Natural history and immunopathogenesis of type 1 diabetes.DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes.Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes.Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy.Buccal spray insulin (Oralgen) for type 2 diabetes: what evidence?Epigenetics in autoimmune diseases with focus on type 1 diabetes.Latent autoimmune diabetes in the adults (LADA) in Asia: from pathogenesis and epidemiology to therapy.Prevention of type 2 diabetes mellitus: is it feasible?Benefits of caloric restriction for cardiometabolic health, including type 2 diabetes mellitus risk.Combination immunotherapies for type 1 diabetes mellitus.The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care.SLEEPING CUPID BY CARAVAGGIO: WHAT DIAGNOSIS?Goiter in paintings by Rogier van der Weyden (1399-1464).
P50
Q27012497-4FB88D44-BB08-4E4B-83E0-578B9672AE3EQ30538087-737AB499-EA61-4297-8CF7-CAF3ADB94160Q33958775-50E25661-E9DA-4B04-804B-32E6C2989C97Q34084512-CA4801F1-AC51-41DC-BF34-5954B7A9EE89Q34311324-8B9D59FA-E205-42E2-BA06-C46A692F6FABQ34353547-C8389E03-586B-4201-84F3-BF8179F3B1D8Q34390728-195021B4-0437-4213-86D9-D84AE1DAE638Q34669209-46A90D09-B96E-4F54-B61B-CEFC0383A61BQ34681018-EA42B0B7-A17D-491D-B17D-88FDD05BCC8CQ35048490-8B68562F-F7E8-4CD2-936F-DDDABD88707BQ35360844-BA2DF252-0E19-4831-9222-1D60A3B8214FQ35404985-01AB2B83-E239-4278-A9C6-ADA6FAED1BECQ35768907-A9B4A921-3A52-4009-940A-ADEF26D3EAE3Q36215679-E1BFF0A5-71BA-40B2-AC96-4A99F8B87FC5Q36588428-605DA292-4D2E-4804-8D90-E456E16F4838Q36625037-09E93B82-AC07-400D-BFEB-E54EB67DBCF3Q36701619-49AE1DC9-CC75-4267-9F49-66766BB6C9F9Q36783740-BDC94B6E-BF0D-4D96-A169-652DB7B357F1Q36900001-6E15B9E8-6D09-414C-A60F-8D0460F2C493Q37275651-CD6A7896-2725-47E9-AFF7-125E113F766AQ37307777-9DCAE036-89D5-4CD6-B6F9-404E407C5637Q37406678-D618F7A2-4CD3-4808-B9B2-098ED0DC00BFQ37417014-B9FD7D03-E46A-491B-A321-5B34D9473C47Q37429006-4F28908A-A895-406C-8B91-78788BB20091Q37577137-10BCB0C3-FC4E-4C91-9C52-B2A0ED9F8EA9Q37627297-EDF88625-8FAC-4291-907F-D10E7B4DC010Q37759264-3C4C91B4-D514-4768-A575-059A06C7E405Q37772470-CF44FCE5-76A9-4DE8-85DE-B81DF09E926AQ37900639-8FCAD8DB-4738-42AB-897B-386AC3E36C44Q37921823-FF24CE2F-D6DB-4833-9128-E83F7CAA9DA2Q37969921-B853E176-E0EC-471C-8B66-20ABFF8C9CE4Q38003648-E221A04E-E115-4F05-9295-E9A4BCCAC406Q38062497-40364394-7E1D-4375-AFFE-4C4E49AE9AA9Q38071010-815AB5AE-C6E6-424A-9B32-B510362B39E9Q38172492-E37CCF1D-2E26-4EC7-A8DE-7B70B4C5D788Q38188495-B52E39D2-294E-4DE6-B214-F2462B91BC47Q38358009-F5AB9EDA-0B26-4048-BBD4-498B371A5A23Q38386131-50F22BA4-0937-4E9C-95CA-6DBA1B9EEDC3Q38401355-A137E860-6B7F-4EE7-8836-ECCCF7009452Q38415893-A7D50F31-9E24-44B0-BBF7-76FDF9D2F697
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Paolo Pozzilli
@ast
Paolo Pozzilli
@en
Paolo Pozzilli
@es
Paolo Pozzilli
@nl
Paolo Pozzilli
@sl
type
label
Paolo Pozzilli
@ast
Paolo Pozzilli
@en
Paolo Pozzilli
@es
Paolo Pozzilli
@nl
Paolo Pozzilli
@sl
prefLabel
Paolo Pozzilli
@ast
Paolo Pozzilli
@en
Paolo Pozzilli
@es
Paolo Pozzilli
@nl
Paolo Pozzilli
@sl
P214
P106
P21
P214
P31
P496
0000-0001-5090-636X
P735
P7859
lccn-n88067301